These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18820131)

  • 1. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
    Weisberg E; Roesel J; Bold G; Furet P; Jiang J; Cools J; Wright RD; Nelson E; Barrett R; Ray A; Moreno D; Hall-Meyers E; Stone R; Galinsky I; Fox E; Gilliland G; Daley JF; Lazo-Kallanian S; Kung AL; Griffin JD
    Blood; 2008 Dec; 112(13):5161-70. PubMed ID: 18820131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and characterization of novel mutant FLT3 kinase inhibitors.
    Weisberg E; Choi HG; Barrett R; Zhou W; Zhang J; Ray A; Nelson EA; Jiang J; Moreno D; Stone R; Galinsky I; Fox E; Adamia S; Kung AL; Gray NS; Griffin JD
    Mol Cancer Ther; 2010 Sep; 9(9):2468-77. PubMed ID: 20807780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
    Park IK; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA
    Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.
    Weisberg E; Kung AL; Wright RD; Moreno D; Catley L; Ray A; Zawel L; Tran M; Cools J; Gilliland G; Mitsiades C; McMillin DW; Jiang J; Hall-Meyers E; Griffin JD
    Mol Cancer Ther; 2007 Jul; 6(7):1951-61. PubMed ID: 17620426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.
    Weisberg E; Barrett R; Liu Q; Stone R; Gray N; Griffin JD
    Drug Resist Updat; 2009 Jun; 12(3):81-9. PubMed ID: 19467916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
    Weisberg E; Boulton C; Kelly LM; Manley P; Fabbro D; Meyer T; Gilliland DG; Griffin JD
    Cancer Cell; 2002 Jun; 1(5):433-43. PubMed ID: 12124173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
    Waldeck S; Rassner M; Keye P; Follo M; Herchenbach D; Endres C; Charlet A; Andrieux G; Salzer U; Boerries M; Duyster J; von Bubnoff N
    Mol Oncol; 2020 Apr; 14(4):779-794. PubMed ID: 31955503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
    Heidel F; Solem FK; Breitenbuecher F; Lipka DB; Kasper S; Thiede MH; Brandts C; Serve H; Roesel J; Giles F; Feldman E; Ehninger G; Schiller GJ; Nimer S; Stone RM; Wang Y; Kindler T; Cohen PS; Huber C; Fischer T
    Blood; 2006 Jan; 107(1):293-300. PubMed ID: 16150941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.
    Weisberg E; Roesel J; Furet P; Bold G; Imbach P; Flörsheimer A; Caravatti G; Jiang J; Manley P; Ray A; Griffin JD
    Genes Cancer; 2010 Oct; 1(10):1021-32. PubMed ID: 21779428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
    Seedhouse CH; Hunter HM; Lloyd-Lewis B; Massip AM; Pallis M; Carter GI; Grundy M; Shang S; Russell NH
    Leukemia; 2006 Dec; 20(12):2130-6. PubMed ID: 17066094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
    Möllgård L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsäter K; Fioretos T; Andersson A; Paul C; Lehmann S
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):439-48. PubMed ID: 17960382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
    von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
    Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.
    Lee HK; Kim HW; Lee IY; Lee J; Lee J; Jung DS; Lee SY; Park SH; Hwang H; Choi JS; Kim JH; Kim SW; Kim JK; Cools J; Koh JS; Song HJ
    Blood; 2014 Apr; 123(14):2209-19. PubMed ID: 24532805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
    Kancha RK; Grundler R; Peschel C; Duyster J
    Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2- and FLT3-inhibitors in the treatment of
    Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
    Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
    Weisberg E; Liu Q; Nelson E; Kung AL; Christie AL; Bronson R; Sattler M; Sanda T; Zhao Z; Hur W; Mitsiades C; Smith R; Daley JF; Stone R; Galinsky I; Griffin JD; Gray N
    Leukemia; 2012 Oct; 26(10):2233-44. PubMed ID: 22469781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance in mutant FLT3-positive AML.
    Weisberg E; Sattler M; Ray A; Griffin JD
    Oncogene; 2010 Sep; 29(37):5120-34. PubMed ID: 20622902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
    Garcia JS; Stone RM
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.